Search Results - "Glazer, William M"

Incidence of Tardive Dyskinesia With Atypical Versus Conventional Antipsychotic Medications: A Prospective Cohort Study by WOODS, Scott W, MORGENSTERN, Hal, SAKSA, John R, WALSH, Barbara C, SULLIVAN, Michelle C, MONEY, Roy, HAWKINS, Keith A, GUEORGUIEVA, Ralitza V, GLAZER, William M

“…Most previous studies of the incidence of tardive dyskinesia with atypical antipsychotics compared with conventional antipsychotics have not had tardive…”
Get full text

Trusting one's physician by Glazer, William M

Get full text

Who Receives Long-Acting Antipsychotic Medications? by Glazer, William M

“…US clinicians, compared with many non-US clinicians, resist using long-acting antipsychotics. An examination of the cultural forces that may drive a punitive…”
Get full text

Visions for Best Practices in Using Coercion in Mental Health Care by GELLER, Jeffrey L, GLAZER, William M

Get full text

Best Practices: Visions for Best Practices in Using Coercion in Mental Health Care by Geller, Jeffrey L, Glazer, William M

“…With benchmarks we can strive to improve involuntary outpatient treatment practices with a goal of ensuring that it is employed as appropriately and…”
Get full text

Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality by Glazer, W M

“…The most frequent problems associated with the older generation of antipsychotic agents are extrapyramidal side effects (EPS) and tardive dyskinesia…”
Get full text

Expected incidence of tardive dyskinesia associated with atypical antipsychotics by Glazer, W M

“…Given the problematic nature of tardive dyskinesia in persons taking conventional antipsychotics, evaluation of newer atypical antipsychotic agents should…”
Get full text

Review of incidence studies of tardive dyskinesia associated with typical antipsychotics by Glazer, W M

“…Unless researchers make an organized effort, patients with tardive dyskinesia are difficult to study and easily lost to follow up. Because there is no…”
Get full text

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol by Beasley, C M, Dellva, M A, Tamura, R N, Morgenstern, H, Glazer, W M, Ferguson, K, Tollefson, G D

“…Tardive dyskinesia is important in the side-effect profile of antipsychotic medication. The development of tardive dyskinesia was evaluated in patients treated…”
Get more information

Deciphering the Cost Impact of Managed Care in Medicaid by Glazer, William M., Goldman, Howard H.

“…In the 1990s, Florida had initiated a model program in the Tampa Bay area by means of a 1915(b) waiver that required psychiatric patients receiving Medicaid to…”
Get full text

Pain and the brain by Arnold, Lesley M, Jain, Rakesh, Glazer, William M

“…Chronic pain is difficult to diagnose and treat, and is often comorbid with psychiatric conditions. Pain and mood disorders may share neurologic pathways and a…”
Get full text

Tactics and technologies to manage nonadherence in patients with schizophrenia by Glazer, William M., Byerly, Mathew J.

“…The occurrence of treatment nonadherence among patients with schizophrenia is clinically significant. However, studies show that clinicians do not make…”
Get full text

Clozapine reduces violence and persistent aggression in schizophrenia by Glazer, W M, Dickson, R A

“…Violence and persistent aggression are serious problems in the general population and among certain psychiatric patients. Violence and persistent aggression…”
Get full text

A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients by Glazer, W M, Ereshefsky, L

“…The discrepancy between supply and demand in health care today requires that psychiatrists and other providers of patient care expand their traditional role…”
Get full text

Are We Ready to Ration Psychiatric Medications? by Glazer, William M

Get full text

Are We Treating Schizophrenia Effectively? Understanding the Primary Outcomes of the CATIE Study by Glazer, William M., Conley, Robert R., Citrome, Leslie

“…The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study for schizophrenia was designed to independently evaluate the effectiveness of…”
Get full text

Does loxapine have "atypical" properties? Clinical evidence by Glazer, W M

“…Given findings at a pharmacologic level that loxapine has a ratio of serotonin (5-HT2) and dopamine (D2) binding affinity similar to that of the atypical…”
Get full text

A novel, point-of-care test for Lithium levels: Description and reliability by GLAZER, William M, SONNENBERG, John G, REINSTEIN, Michael J, AKERS, Raymond F

“…Lithium is a highly effective agent for numerous psychiatric disorders but requires therapeutic monitoring because of its narrow therapeutic index. This…”
Get full text

Formulary decisions and health economics by Glazer, W M

“…Because of increasing concerns about health care costs, physicians must consider the cost-effectiveness of a treatment strategy, as well as its efficacy and…”
Get full text

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia by GLAZER, W. M, JOHNSTONE, B. M

“…Medications comprise a minor portion of the costs of schizophrenia, but may have a major impact on the likelihood of successful outcome of care. Novel…”
Get full text